Tratamiento de hepatitis C y psicosisa propósito de dos casos clínicos

  1. Román Avezuela, Nuria
  2. Esteve Díaz, N.
  3. Martín, María del Valle
  4. Domarco Manrique, Leticia
  5. Domínguez Longás, Alberto
  6. García Cabeza, Ignacio
Revista:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Año de publicación: 2014

Volumen: 34

Número: 121

Páginas: 135-141

Tipo: Artículo

DOI: 10.4321/S0211-57352014000100008 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista de la Asociación Española de Neuropsiquiatría

Resumen

El virus de la hepatitis C (VHC) es la principal causa de patología hepática El tratamiento habitual para la infección crónica del VHC es la combinación de interferón (IFN) pegilado alfa y ribavirina. Los efectos adversos psiquiátricos asociados a dicho tratamiento son: ansiedad, depresión, manía, deliriumy psicosis (aunque ésta es poco habitual).Los pacientes con enfermedades mentales graves y/o adicciones a sustancias presentan respuestas virológicas al tratamiento para la infección por VHC similare sa la población general. No existen datos definitivos que avalen que estos pacientes no puedan ser tratados e incluso retratados aún cuando el tratamiento inicial no haya sido eficaz o hayan sufrido descompensaciones psicóticas atribuibles al mismo, aunque sí se aconseja hospitalizar al paciente para poder hacer un control más estrecho. Los pacientes diagnosticados de psicosis crónica no deben ser excluidos si están estables psicopatológicamente, realizan un seguimiento psiquiátrico regular, presentan una buena adherencia al tratamiento y disfrutan de un ambiente contenedor.La decisión debe tomarse de forma individualizada.El tratamiento de los síntomas psicóticos producidos por el tratamiento con IFN alfa y ribavirina consiste en cesar el tratamiento antiviral e introducir antipsicóticos.En la mayoría de los casos los síntomas remiten,pero hay descritos casos resistentes

Referencias bibliográficas

  • (1) World Health Organization: Hepatitis C. Weekly Epidemiological Record, 1997; 72:341–344.
  • (2) McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485–1492.
  • (3) Collier J, Chapman R: Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs 2001; 15:225–238.
  • (4) Shepherd J, Brodin H, Cave C, et al: Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8:1–125.
  • (5) Jacobson IM, Gonzalez SA, Ahmed F, et al: A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100:2453–2462.
  • (6) Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferonbased therapy complications. J Psychiatr Pract 2003; 9:93–110.
  • (7) Hosoda S, Takimura H, Shibayama M, et al: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54:565– 572.
  • (8) Vignau J, Karila L, Costisella O, et al: Hepatitis C, interferon a and depression: main physiopathologic hypothesis. Encephale, 2005. 31(3): p. 349-357.
  • (9) Fattovich G, Giustina G, Favarato S, et al: A survey of adverse effects in 11241 patients with chronic viral hepatitis treated with interferon alpha. J Hepatol, 1996. 24: p. 38-47.
  • (10) Cabrera Gómez JA, Cordero Gutiérrez JR, Fernández LO, et al: Treatment of squizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy, 1993. 3:7: p. 27-37.
  • (11) Katila H, Cantell C, Appelberg B, et al: Interferon alpha as adjuvant treatment in chronic squizophrenia. Neuropsychobiology, 1993. 28: p. 192-196.
  • (12) Myint AM, Schwarz MJ, Steinbusch HWM, et al: Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Disor, 2009. 24: p. 55-68.
  • (13) Cheng YC, Chen CC, Ho AS, et al: Prolonged Psychosis Associated With Interferon Therapy in a Patient With Hepatitis C: Case Study and Literature Review. Psychosomatics, 2009. 50:5: p. 538-542.
  • (14) Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and inteferon-based therapy complications. J Psychiatr Pract, 2003. 9: p. 93-110.
  • (15) Schaefer M, Schwaiger M, Pich M, et al: Neurotransmiter changes by interferon alpha and therapeutic implications. Pharmacopsychiatry, 2003. 36:S: p. 203-206.
  • (16) Malyszczak K, Inglot M, Pawlowski T, et al: Neuropsychiatric symptoms related to interferon alpha. Psychiatra Polska, 2006. 40: p. 787-797.
  • (17) Lerner DM, Stoudemire A, Rosestein DL: Neuropsychiatric toxicity associated with cytokine therapy. Psychosomatics, 1999. 40: p. 428-435.
  • (18) Schaefer M, Hinzpeter A, Mohman A, et al: Hepatitis C Treatment in “Difficult-toTreat” Pscychiatric Patients with Pegylated Interferon-Alpha and Ribavirin: Response and Psychiatric Side Effects. Hepatology, 2007. 46:4: p. 991-998.
  • (19) Lauer GM, Walker BD: Hepatitis C virus infetion. New England Journal of Medicine, 2001. 345: p. 41-52.
  • (20) Rowan PJ, Tabasi S, Abdul-Latif M, et al: Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol, 2004. 38: p. 530-534.
  • (21) Rifai MA, Moles JK, Short DD: Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv, 2006. 57: p. 570-572.
  • (22) Geppert CM, Arora S: Widening the door: the evoluation of hepatitis C in patients with psychiatric disorders. Hepatology, 2007. 46: p. 957-959.
  • (23) Silverman BC, Kim AY, Freudenreich O: Interferon-Induced Psychosis as a “Psychiatric Contraindication” to Hepatitis C Treatment: A Review and Case-Based Discussion. Psychosomatics, 2010. 51:1: p. 1-7.
  • (24) Quarantini LC, Bressan RA, Galvão A, et al: Incidence of psychiatric side effects during pegylated inteferon-alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver International, 2007. 2007: p. 1098-1102.
  • (25) Álvarez-Uria G, Day JN, Nasir AJ, et al: Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver International, 2008. 2008: p. 1051-1055.
  • (26) Sockalingam S, Chekkera S, Stergiopoulos V: Managing the neuropsychiatric complications of hepatitis C treatment. British Journal of Hospital Medicine, 2007. 68: 10: p. 520-525.
  • (27) Telio D, Sockalingam S, Stergiopoulos V: Persistent psychosis after treatment with interferon alpha: A case report. Psychopharmacol, 2006. 26: p. 446-447.
Fuente de los datos: Dialnet